EG30 for the treatment of Alzheimer's disease
Project ID : 10-2011-274
EG-30: clinical phase drug for AMD and Glaucoma
EG-30 – the highlights:
· Excellent safety profile in healthy volunteers and glaucoma patients
•Low systemic exposure
•No increase in IOP in glaucoma patients treated with EG-30 for 16days (eye drops)
·Extensive safety and efficacy preclinical package:
•EG-30 inhibit the formation of amyloid beta oligomers and serve as a cytoprotectant agent
•Efficacy in dry AMD and glaucoma animal models
•Safety and toxicology including 6 months toxicology studies in rabbits and monkeys
·An FDA approved development path allowing a single confirmatory study for FDA approval of EG-30 for both glaucoma and dry AMD
·New derivatives for Alzheimer treatment
Project manager
Elisha Natan
Director BD
Project researchers
Ehud Gazit
T.A.U Tel Aviv University, Life Sciences
Molecular Microbiology-Biotechnology
Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at the university to industry's attention. The company provides the legal and commercial frameworks for inventions made by TAU faculty, students and researchers, protecting discoveries with patents and working jointly with industry to bring scientific innovations to the market.
Create your free account to connect with RAMOT at Tel Aviv University Ltd. and thousands of other innovative organizations and professionals worldwide
Send a request for information
to RAMOT at Tel Aviv University Ltd.
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
